CTLA4 and mantle cell lymphoma: In a phase I clinical trial of ipilimumab after allo-HSCT, complete remission was achieved in two patients with Hodgkin’s lymphoma and partial remission in one patient with refractory mantle cell lymphoma, suggesting that targeting CTLA-4 is feasible [49].